Chronic Kidney Diseases, Diabetes Mellitus, Hypertension, Hyperuricemia, Obesity
Conditions
Keywords
chronic kidney disease, metabolic diseases, biomarker, functional imaging techniques
Brief summary
With the development of China's economy, people's living standard have improved, and the dietary structure have changed. Metabolic diseases, such as hypertension, diabetes, hyperuricemia and obesity have gradually become an important health burden in China. The pathophysiological mechanism of renal injury caused by metabolic diseases has always been a hotspot of research. Currently, it is believed that various mechanisms including the activation of Renin-Angiotensin-Aldosterone System, vascular endothelial dysfunction, oxidative stress and inflammatory process may be involved. Although there are differences in renal pathological manifestations caused by different metabolic diseases, the kidney will eventually present ischemic changes and fibrosis with the progression of the disease. So there must be some common pathogenesis. This study is designed to build a disease cohort of patients with chronic kidney disease caused by metabolic diseases, to identify risk factors leading to disease progression and to explore biomarkers for early diagnosis and treatment of kidney damage.
Interventions
DIAGNOSTIC_TESTBiomarkers
Blood,urine and imaging biomarkers for early diagnosis and prediction of prognosis.
Sponsors
Peking Union Medical College Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* The diagnosis of metabolic diseases were confirmed; * Be able to understand the process of the research; * Volunteer for participation and be able to sign the informed consent.
Exclusion criteria
* Age \<18 yrs or \>80yrs; * Patients with primary and secondary glomerular diseases * Patients with other comorbidities that could affect the volume or the components of the kidney, such as renal cysts, polycystic kidney disease, medullary sponge kidney, hydronephrosis, renal artery stenosis, renal vein thrombosis and/or renal tumors; * Contraindications for MRI examination; * Pregnant or lactation patients; * Patients with unstable vital signs, failure of other organs or dysphoria.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants with End Stage Renal Disease | 3 years | End Stage Renal Disease |
| Number of Participants with Adverse cardiovascular events | 3 years | Adverse cardiovascular events |
| Number of Participants with all cause death | 3 years | All cause death |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants with eGFR decline | 3 years | the decline of eGFR during follow-up |
| Advanced Intelligence Assessment with Mini-Mental State Examination (MMSE) | 3 years | The MMSE is scored on a 30-point scale, with items that assess orientation (temporal and spatial; 10 points), memory (registration and recall; 6 points), attention/concentration (5 points), language (verbal and written; 8 points), and visuospatial function (1 point) . While different cutoff points have been used across studies, scores ≤23 are most commonly regarded as abnormal and indicative of cognitive impairment. |
| Number of Participants with Complications of CKD | 3 years | The complications of CKD |
| Life quality assessment with short form-36 (SF-36) | 3 years | The SF-36 is a patient-reported instrument designed to assess overall health status; it is usually utilized to measure patients' quality of life and used primarily in research. Increasing SF-36 scores are indicative of improving health status. |
Countries
China
Contacts
Primary ContactYan Liu
Outcome results
None listed